New Drug Candidate for Treating Diabetes

In preclinical studies, an orally active small molecule compound was shown to activate insulin receptors and cause enhanced glucose transport into muscle and liver cells and cause improvement in blood sugar levels in animal models of diabetes.

The compound (TLK19781) is an insulin receptor activator being developed by Telik, Inc. (S. San Francisco, CA, USA), using its proprietary Trap drug discovery technology that aids the rapid and efficient discovery of small molecule candidates. The company has received notices of allowance on three US patents pending that cover the composition of matter and uses of these and other insulin receptor activator compounds. Telik has retained worldwide commercial rights to the compound and its other insulin receptor activator compounds except in Japan and other Asian countries, where its partner, Sanwa Kagaku Kenkyusho Co., Ltd., has exclusive rights.

Telik's most advanced drug development candidate is TLK286, a tumor-activated small molecule drug now in phase 2 clinical trials for treating ovarian, nonsmall cell lung, colorectal, and breast cancer.

"We believe these patents, along with others that have been issued or filed, provide an excellent intellectual property base to support our development program,” said Robert T. Lum, Ph.D., vice president, preclinical development, Telik.



Related Links:
Telik